Wockhardt (NSE:WOCKPHARMA) ROCE %: 13.67% (As of Mar. 2026)


NSE:WOCKPHARMA Wockhardt Ltd NSE:WOCKPHARMA
64 GF Score
Price ₹1,857.40
GF Value ₹1,267.12
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Wockhardt ROCE %?

Wockhardt NSE:WOCKPHARMA -3.03% 64 ROCE % is 13.67% as of Mar. 2026. GuruFocus rates NSE:WOCKPHARMA with a GF Score™ of 64/100 and a GF Value™ of ₹1,267.12 (Significantly Overvalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Wockhardt's annualized ROCE % for the quarter that ended in Mar. 2026 was 13.67%.

Wockhardt  (NSE:WOCKPHARMA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Wockhardt ROCE % Related Terms

Wockhardt ROCE % Historical Data

* Premium members only.

The historical data trend for Wockhardt's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wockhardt ROCE % Chart

Wockhardt Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.66 -7.15 -2.83 4.35 6.89

Wockhardt Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.71 -4.00 8.59 7.47 13.67
NSE:WOCKPHARMA
64GF Score
Wockhardt Ltd NSE:WOCKPHARMA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wockhardt ROCE % Calculation

Wockhardt's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=4510/( ( (81350 - 20420) + (86150 - 16220) )/ 2 )
=4510/( (60930+69930)/ 2 )
=4510/65430
=6.89 %

Wockhardt's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=9560/( ( (0 - 0) + (86150 - 16220) )/ 1 )
=9560/( ( 0 + 69930 )/ 1 )
=9560/69930
=13.67 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 13.67% mean?
Wockhardt (NSE:WOCKPHARMA) has a ROCE % of 13.67% as of Mar. 2026.
Is Wockhardt's ROCE % too high?
Wockhardt's current ROCE % is 13.67%. The Drug Manufacturers industry median ROCE % is 7.03. Wockhardt's value of 13.67% is 94.5% above this industry median. Overall, Wockhardt has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wockhardt's ROCE % compare to ZTS and UTHR?
Wockhardt's ROCE % of 13.67% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. Wockhardt's value of 13.67% is 94.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wockhardt's current ROCE % of 13.67% is 94.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wockhardt's current ROCE % is 13.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wockhardt stock overvalued right now?
Based on GuruFocus' analysis, Wockhardt (NSE:WOCKPHARMA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,267.12, compared to a current price of ₹1,857.40 — trading 46.6% above its estimated fair value. The current ROCE % is 13.67% and 94.5% above the Drug Manufacturers industry median of 7.03. Wockhardt's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Wockhardt (NSE:WOCKPHARMA), the current ROCE % is 13.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wockhardt (NSE:WOCKPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued. The current stock price of ₹1,857.40 is trading 46.6% above its estimated GF Value™ of ₹1,267.12. GuruFocus considers Wockhardt to be Significantly Overvalued.

Key valuation signals for NSE:WOCKPHARMA:

  • ROCE %: 13.67%
  • GF Value™: ₹1,267.12 vs. price of ₹1,857.40 (46.6% above fair value)
  • GF Score™: 64/100 with 5 warning signs
  • Industry Position: 94.5% above the Drug Manufacturers median

No single metric tells the full story. See the NSE:WOCKPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Wockhardt Business Description

Other Exchanges 532300:India
Address Bandra-Kurla Complex, Wockhardt Towers, Bandra East, Mumbai, MH, IND, 400051
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
64GF Score

Get the complete analysis for NSE:WOCKPHARMA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,857.40
Price
₹1,267.12
GF Value